Omacor is a proprietary drug , a mixture of omega-3 polyunsaturated fatty acid ethyl esters (90%). It contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are related to essential (essential) fatty acids, in a ratio of 1.2 / 1. It is used to normalize lipid metabolism , as well as to prevent repeated myocardial infarction. The drug is registered in 40 countries, including the European Union and the USA, approved by the FDA as a medicine [3] .
| Omacor | |
|---|---|
| Omacor | |
| Active substance | |
| EPA \ DHA ethyl esters | |
| Classification | |
| Farmakol. Group | Other lipid-lowering drugs [1] |
| ATX | |
| ICD-10 | |
| Dosage Forms | |
| capsules [2] | |
Content
Clinical Trials
Omacor research work includes two large, multicenter, randomized, placebo-controlled trials conducted by the GISSI team.
- GISSI-P, 1999. Against the background of taking Omacor after 3 months of use, the overall mortality significantly decreased by 20%, mortality from fatal arrhythmias decreased significantly by 45% after 4 months from the start of treatment. [four]
- GISSI-HF, 2008. Against the background of the use of Omacor in patients with heart failure, there was a significant decrease in mortality by 9% reliably and by 14% in patients who followed the study protocol. Hospitalization due to arrhythmias decreased [5] .
Pharmacological action
Omacor acids - EPA and DHA are embedded in the ion channels (mainly sodium and calcium) of heart cells and block the initiation of arrhythmias, especially in ischemic myocardium, after myocardial infarction, in chronic heart failure. Reduces the content of triglycerides (as a result of a decrease in the concentration of very low density lipoproteins , VLDL), affects hemostasis (reducing the synthesis of thromboxane A2 and slightly increasing the coagulation time).
It inhibits the synthesis of triglycerides in the liver (due to inhibition of the esterification of EPA and DHA). A decrease in the level of triglycerides is promoted by an increase in the oxidation of fatty acids by peroxide P (a decrease in the amount of free fatty acids necessary for the synthesis of triglycerides).
The increase in high density lipoproteins (HDL) is very slight (significantly less than after taking fibrates) and is not constant. [2]
Application
Recommended for the treatment of IHD (angina pectoris) and myocardial infarction according to the recommendations of the All-Russian Scientific Society of Cardiology, 2008 and the recommendations of the European Society of Cardiology, 2005 [6] [7] .
Notes
- ↑ Omacor . Register of medicines . ReLeS.ru (07.07.2006). Date of treatment July 13, 2009. Archived March 22, 2012.
- ↑ 1 2 Search the database of drugs, search options: Trade name - Omacor , the flags “Search in the register of registered drugs” , “Search TKFS” , “Show drug forms” unspecified (unavailable link) . Circulation of drugs . Federal State Institution “Scientific Center for Expertise of Medical Application Tools” of the Russian Healthcare Supervision Service of the Russian Federation (05.26.2009). - A typical clinical and pharmacological article is a by-law and is not protected by copyright in accordance with part four of the Civil Code of the Russian Federation No. 230-FZ of December 18, 2006. Date of treatment July 13, 2009. Archived August 22, 2011.
- ↑ FDA Drug Approval Package
- ↑ Omacor gelatine capsules, 1 / d (0.9g / d EPA + DHA daily)
- ↑ Rupp H. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. (English) // Advances in therapy. - 2009. - Vol. 26, no. 7 . - P. 675-690. - DOI : 10.1007 / s12325-009-0045-2 . - PMID 19629408 .
- ↑ Guidelines for the diagnosis and treatment of stable angina pectoris. The text of the recommendations was prepared by the Working Group on Stable Angina Pectoris of the European Society of Cardiology, chaired by Kim Fox, 2006
- ↑ Fox K. , Garcia MA , Ardissino D. , Buszman P. , Camici PG , Crea F. , Daly C. , De Backer G. , Hjemdahl P. , Lopez-Sendon J. , Marco J. , Morais J. , Pepper J. , Sechtem U. , Simoons M. , Thygesen K. , Priori SG , Blanc JJ , Budaj A. , Camm J. , Dean V. , Deckers J. , Dickstein K. , Lekakis J. , McGregor K. , Metra M. , Morais J. , Osterspey A. , Tamargo J. , Zamorano JL Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. (English) // European heart journal. - 2006. - Vol. 27, no. 11 . - P. 1341-1381. - DOI : 10.1093 / eurheartj / ehl001 . - PMID 16735367 .